Dyax does first patient in DX-2930 HAE trial


Dyax (DYAX) says the first subject has been dosed in a Phase 1 trial for subQ DX-2930, the company's fully human monoclonal antibody inhibitor of plasma kallikrein. (PR)

SubQ DX-2930 is being developed for the prevention of HAE attacks.

Other notable HAE drugs: BCRX's BCX-4161 and VPHM's Cinryze

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs